

GLAXOSMITHKLINE PLC  
Form 6-K  
February 17, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons**

The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 16 February 2009 of an increase in their notional interests in Ordinary shares at a price of £12.34 per share and Ordinary Share ADRs at a price of \$35.50 per ADR following the notional re-investment of the dividend to be paid to shareholders on 9 April 2009

	<b>Ordinary shares</b>	<b>ADRs</b>
Mr A	6,531.	
P	55	
Witty		
Mr J	4,597.56	
S		
Heslop		
Dr M	409.00	2,035.03
M		
Slaoui		
Mrs C E Bruck Slaoui	32.60	46.30
Mr S M Bicknell	344.43	
Mr J	3	
M	,	
Clarke	427.92	
Mr M Dunoyer	1	
	,	
	291.04	
Mr E J Gray	1,070.07	
Mr S A Hussain	633.20	
Mr D Learmouth	704.92	
Mr W C Louv		818.52
Mr D		1,734.29
J		
Phelan		
Dr D Pulman		1,126.16
Mr D S Redfern	525.32	
Mr J R Stéphenne	1,1	

	84.19	
Ms C Thomas	395.32	
Mr D E Troy		804.54

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a)

V A Whyte  
Deputy  
Company Secretary

17  
February 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 17, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc